Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Trump Signs Order to Cut Routine Childhood Vaccines 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Amazon Prime Air Cargo Plane Crash Kills Five at Miami Airport 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Nvidia CEO Says AGI Has Arrived With OpenAI GPT-6 Astra 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Brazil Court Suspends Sigma Lithium Mine Operations 
Add as a preferred source on Google
AstraZeneca reported robust first-quarter 2026 earnings, driven by strong demand for its oncology and rare disease treatments, delivering solid revenue growth and beating analyst expectations. The U.K.-based pharmaceutical giant posted total revenue of $15.29 billion, up from $13.59 billion in the same period last year and above the consensus estimate of $14.94 billion. On a constant currency basis, revenue increased 8% year-over-year, highlighting sustained global demand across its core therapeutic areas.
The company’s oncology portfolio remained a key growth engine, with sales rising 16% year-over-year at constant currency to $6.8 billion. This segment now contributes approximately 44% of AstraZeneca’s total revenue, underscoring its strategic importance. Several flagship cancer drugs delivered notable performance, including Imfinzi, which surged 30% to $1.7 billion, and Enhertu, which jumped 34% to $831 million. Tagrisso, another leading lung cancer therapy, also posted growth, increasing 5% to $1.8 billion.
Core earnings per share (EPS), a key profitability metric that excludes one-off items, came in at $2.58, surpassing analyst forecasts of $2.54 and marking a 5% increase at constant currency. Core operating profit rose 12% to $4.25 billion, reflecting improved operational efficiency and continued investment in commercial capabilities. Meanwhile, net profit climbed to $3.08 billion from $2.92 billion a year earlier.
CEO Pascal Soriot emphasized the company’s strong commercial execution and ongoing investments, noting that AstraZeneca is well-positioned for multiple upcoming product launches and clinical readouts in 2026. The company reiterated its full-year guidance, expecting revenue growth in the mid-to-high single-digit range and core EPS growth in the low double digits.
With continued momentum in its oncology pipeline and expanding rare disease portfolio, AstraZeneca remains a major player in the global pharmaceutical market, attracting investor attention as it works toward its long-term growth ambitions through 2030 and beyond.
